Literature DB >> 24165950

Targeted therapies: programmed death: improving DLBCL.

Alessia Errico.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24165950     DOI： 10.1038/nrclinonc.2013.200

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

Authors:  Philippe Armand; Arnon Nagler; Edie A Weller; Steven M Devine; David E Avigan; Yi-Bin Chen; Mark S Kaminski; H Kent Holland; Jane N Winter; James R Mason; Joseph W Fay; David A Rizzieri; Chitra M Hosing; Edward D Ball; Joseph P Uberti; Hillard M Lazarus; Markus Y Mapara; Stephanie A Gregory; John M Timmerman; David Andorsky; Reuven Or; Edmund K Waller; Rinat Rotem-Yehudar; Leo I Gordon
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.